Biotech Values

[Checkpoint]

Bristol combination data is superior to Merck's solo data. In terms of robustness of response, in terms of durability. One can't help and feel after seeing Bristol's combination data and conclude they are turning the bodies immune system on at a higher more efficacious level then Merck's solo data. It's not even clear Merck's PD1 is better then Bristol's. one thing is clear with this combination in phase 3 in Melanoma and phase 2 in lung and renal Bristol might have made many oncology agents irrelevant. Maybe, obviously we need more data. The next big test of this thesis is the combination lung cancer data.